Stents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.

Similar documents
Drug Eluting Stents: an update Abbott Vascular. All rights reserved.

Guide Wires design and selection Abbott Vascular. All rights reserved.

Radiation Safety Abbott Vascular. All rights reserved.

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION

PCI for Left Anterior Descending Artery Ostial Stenosis

PCI for Long Coronary Lesion

What Stent to Use? JASVINDAR SINGH MD, FACC

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

eluting Stents The SPIRIT Trials

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Nobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

Technical Characteristics of coronary prostheses(stents)

DISAPPEARING STENT: IS THE TIME APPEARED?

Bifurcation stenting with BVS

The titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath

Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες

COMPLEX CASES: LEFT MAIN

BIOFREEDOM: Polymer free Biolimus A9 eluting

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo

PCI for In-Stent Restenosis. CardioVascular Research Foundation

Current DES designs and expansion capacity testing

Medtronic Symposium The Complex Bifurcation Patient: new insights into stent selection

Patient. Clinical data Indications: Operation date. Comorbidities: Patient code Birth date: / /

Lessons for technique and stent choice

Taking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

Drug eluting stents From revolution to evolution. Current limitations

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI

LM stenting - Cypher

Bifurcation Stenting: IVUS and OCT Information

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD

FFR-guided Jailed Side Branch Intervention

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Vascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts

INDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...

DES In-stent Restenosis

Goal: Optimal Stent Deployment

September Peter Barlis. Royal Brompton Hospital, London, UK

Catch-up Phenomenon: Insights from Pathology

COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands

PROMUS Element Experience In AMC

Protection of side branch is essential in treating bifurcation lesions: overview

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

OCT Findings: Lesson from Stable vs Unstable Plaques

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

Moins de 6 mois d antiagrégants après DES?

ReZolve2 Bioresorbable Coronary Scaffold Clinical Program Update

Percutaneous Intervention of Unprotected Left Main Disease

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

New Generation Drug- Eluting Stent in Korea

Non-LM bifurcation studies of importance in 2011

DESolve NX Trial Clinical and Imaging Results

Drug Eluting Stents: Bifurcation and Left Main Approach

EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Next Generation Drug- eluting Stent : Will It Solve the Problem?

CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer

Clinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD

Complex PCI. Your partner in complex PCI: In-stent restenosis (ISR)

OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT

PCI for Ostial Lesion

ABT 578 Elution from Phosphorylcholine: Zomaxx (Abbott)

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland

The BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino

Yukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.

Bench test : Is it still useful? Do we need standardization?

In-Stent Restenosis. Can we kill it?

Bioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals

Drug eluting balloons in CAD

TRIAS HR Pilot Study

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

Bench Insights into Bifurcation Stenting in the DES Era: An Update

Combine the best of both worlds

SKG Congress, 2015 EVOLVE II. Stephan Windecker

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Tailored bifurcation therapy

Drug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester

INTERVENTIONAL CARDIOLOGY Bioresorbable Stents Update: Similarities. Generation BVS

A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries

PCI for Chronic Total Occlusions

Disclosure Eberhard Grube, M.D.

high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

For Personal Use. Copyright HMP 2013

Optical Coherence Tomography for Intracoronary Imaging

Angioplasty Summit TCTAP Technical Aspects of Overview in CTO-PCI Toyohashi Heart Center Takahiko Suzuki, M.D

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

NC EMERGE TM PTCA Dilatation Catheter

Solving the Dilemma of Ostial Stenting: A Case Series Illustrating the Flash Ostial System

Drug Eluting Stent DES Pathology Update What we know, what we do not know

INTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY. SeQuent Please NEO CLINICAL EVIDENCE AND COST / BENEFIT EFFECTIVENESS

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?

Excimer Laser for Coronary Intervention: Case Study RADIAL APPROACH: CORONARY LASER ATHERECTOMY FOR CTO OF THE LAD FOLLOWED BY PTCA NO STENTING

6 th European Bifurcation Club October BUDAPEST. Kissing in simple strategy? Why and how I kiss. Y. Louvard, ICPS, Massy France

Transcription:

Stents selection and optimal implantation: sizes, design, deployment

Stent classification: Mechanism of expansion - Self-expanding - Balloon expandable Design - Mesh structure - Coil - Slotted tube - Ring Composition - Stainless steel - Cobalt based alloy - Tantalum - Nitinol - Inert coating - Active coating - Biodegradable - Multidesign - Custom design 2

Stent Types Self-expanding Stent placed under a sheath Sheath retraction allows stent expansion Balloon-expandable Factory mounted on a balloon delivery system 3

Stent Types 4

Stent Types - Composition - The stainless steel is the most frequently used material, which is proved to be the most reliable based to clinical trials. - Nowadays cobalt-chromium alloys are more and more frequently used. 5

Stent Types - Composition - The peripheral stents are made of nickel-titanium alloys (nitinol). - The biodegradable stents made of magnesium are in trial phase. 6

Stent Manufacturing - Coronary stents are commonly manufactured from tube by laser cutting. - Other manufacturing processes are coiling, spinning or looping from wire. 7

Stent Terminology Self expanding Balloon expandable Stent strut Stent crowns and connectors Stent patterns, closed and open cells Metal-to-artery ratio Unsupported surface area Vessel scaffolding Foreshortening Flexibility and conformability Radiopacity Self-expanding vs. Balloonexpandable Balloon outside the stent / Overhang Stent jail Apposition / Expansion Recoil Radial strength 8

Ideal Stent Flexibility & conformability Good scaffolding High radial strength with minimal recoil Good visibility Minimal foreshortening Side-branch accessibility Appropriate metal-to-artery ratio Biocompatibility Optimal stent delivery system Variety of sizes and lengths 9

What about Technique? You can have a perfect stent but if you don t use a good technique you may as well throw it in the rubbish 10

Avoid under-expansion In BMS bigger is better was the rule In DES under-expansion is still the most important cause of stent faillure. BMS Cypher Taxus Endeavor 11

Good Technique Plaque preparation Adequate implantation pressure Post-dilatation 12

Plaque preparation Balloons Semi compliant High pressure Especial balloons Rotablation 13

Be careful when implanting stents without pre-dilatation!!! Not well expanded implanted stent 45 yearsfemale, smoker as only risk factor?? Proximal LAD 14

Can we follow chart instructions? DES achieved only 75% of manufacturer predicted diameter and 66% of predicted stent area. 24% of SES and 28% of PES did not achieve a final MSA of 5 mm 2 15

Post-dilatation Be generous In Postdilating Stents! 16

Why Post-dilatation? We cannot accurately predict stent expansion by angiography, so one should Iterative IVUS can be be used to to fine-tune the the final MSA during stent implantation - - Angio cannot Be generous postdilating even in very small residual stent stenosis QCA QCA MLD MLD (mm) (mm) 4 4 3.0 3.0 3.1 3.1 3.1 3.1 3 32.5 2.5 2 2 p<0.05 p<0.05 p=ns p=ns p=ns p=ns 1 1 0 0 8ATM 8ATM 12ATM 12ATM 15ATM 15ATM 18ATM 18ATM IVUS IVUS Stent Stent CSA CSA (mm (mm 2 )* 2 )* 12 10 10 7.7 7.7 8 8 6 4 2 0 12 6 4 2 9.2 9.2 10.1 10.1 10.9 10.9 p<0.05 p<0.05 p<0.05 p<0.05 p<0.05 p<0.05 0 8ATM 8ATM 12ATM 12ATM 15ATM 15ATM 18ATM 18ATM *ANOVA P<0.0001 Comparation of IVUS and QCA post stent + adjunt PTCA Iterative angio and IVUS a different atm 17

How postdilate? Non compliant balloons High pressure Adequate size Adequate length ( avoid geographical miss) 18

BMS vs IV. Adverse DES issues (clinical view) Presentation II. Risk assessment III. Build a strategy V. How to deal with the lesion VI. Post PCI treatment ntial techniques and es urcation Before selecting the revascularization technique : investigate the potential problems! tent restenosis er complex lesions l selection iding catheter Problem with prolonged A + C? Risk of surgery in coming months? Suspected compliance issue (+++) Allergy to ASA or Clopidogrel? YES Consider BMS or CABG for complex lesions? ide Wire lloon or other NO tents e PCI treatment non diabetic,?3.5 mm vessel, < 15mm lesion YES Consider BMS? NO ASA+ clopidogrel DES ++ Clearly Inform patient before PCI > SCENARIO 1 2 19

BMS vs DES : Check list for DES sment III. Build a III. strategy Build a strategy IV. Adverse IV. issues Adverse issues V. How to deal V. with How the tolesion deal with the VI. lesion Post PCI treatment VI. Post PCI treatment e Before selecting selecting the revascularization the revascularization technique technique : : tigate investigate the potential the potential problems! problems! em Problem with prolonged with prolonged A + C? A + C? f surgery Risk of surgery in coming months? coming months? Suspected Suspected compliance issue (+++) issue (+++) y to Allergy ASA or to Clopidogrel ASA or Clopidogrel?? YES Consider BMS Consider BMS YES or CABG or CABG for complex for lesions? complex lesions? NO NO iabetic, non diabetic,?3.5 mm?3.5 vessel, mm vessel, m < lesion 15mm lesion YES YES Consider BMS Consider? BMS? NO NO ASA+ clopidogrel ASA+ clopidogrel DES DES ++ Clearly Inform 20 Clearly Inform ++ patient before patient PCI before PCI

election g catheter Wire n or other Risk of surgery in coming months? Suspected compliance issue (+++) Allergy to ASA or Clopidogrel? BMS vs DES (clinical view) NO YES Consider BMS or CABG for complex lesions? ts I treatment non diabetic,?3.5 mm vessel, < 15mm lesion YES Consider BMS? NO ASA+ clopidogrel DES ++ Clearly Inform patient before PCI > SCENARIO 1 2 21

BMS vs DES (clinical view) BMS Short lesions Large reference diameter Second lesion in 2VD Difficult anatomy (tortuosity, calcification) Planned short - term interruption in antiplatelet medication most AMI Lack of reimbursement DES Long lesions Small reference diameter Instent restenosis Chronic total occlusion Good compliance anticipated with ASA+ thienopyridine Adequate reimbursement 22

Mortality in RCTs comparing DES vs BMS Conclusion Drug-eluting stents for the treatment of coronary artery disease do not reduce total mortality when compared with bare metal stents. Preliminary evidence suggests that sirolimus- but not paclitaxel-eluting stents may lead to increased non-cardiac mortality. Long-term follow-up and assessment of cause-specific deaths in patients receiving drug-eluting stents is mandatory to determine the long-term safety of these devices. 23 Source: Nordmann AJ et al, Eur Heart J Oct 2006

Mortality in RCTs comparing DES vs BMS 24 Source: Nordmann AJ et al, Eur Heart J Oct 2006

Mortality in RCTs comparing DES vs BMS 25 Source: Nordmann AJ et al, Eur Heart J Oct 2006

Mortality in RCTs comparing DES vs BMS 26 Source: Nordmann AJ et al, Eur Heart J Oct 2006

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta analysis 38 trials, 18023 pts Cumulative incidence of overall death & cardiac death Source: Stettler et al. Lancet 2007; 370: 937 48 27

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta analysis Cumulative incidence of MI & death or MI Source: Stettler et al. Lancet 2007; 370: 937 48 28

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta analysis Cumulative incidence of Definite SR & TLR Source: Stettler et al. Lancet 2007; 370: 937 48 29

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta analysis Stratified analysis according to presence or absence of diabetes mellitus Cumulative incidence of death or MI Source: Stettler et al. Lancet 2007; 370: 937 48 30

31

DES vs BMS in STEMI : Massachusetts Registry DES BMS Death 2.8 3.1 Death or IM 5.8 6.9 TLR 5.8 12.0 Mauri et al, N Eng J Med 2008 32

Potential Mechanisms for Stent Thrombosis 33

Hypothetic Major Mechanisms? Delayed Endothelialisation Late Stent Thrombosis Abnormal Blood Flow Increased Blood Thrombogenicity 34

Percent Percentage Endothelialization Percent Incomplete Strut Endothelialization is Usual in Patients 100 75 50 25 0 0 25 50 Sirolimus-eluting stent Incomplete coverage Complete coverage Grade 0 Grade 1 Grade 2 Grade 3 75 Bare metal stent Angioscopy at 8 months post SES implantation 100 100 90 80 70 60 50 40 30 20 10 0 BMS DES 1 2 3 4 5 6 7 8 9 11 15 16 17 20 >40 Duration in months Virmani autopsy data 35 Source: Kotani J et al. JACC. 2006,47:2108 Source: Joner M et al. JACC. 2006;48:193.

Cypher A B 65 yo male with h/o Cypher stent placement to the prox LAD and BXVelocity to the distal LAD 15-months prior to non-cardiac death C No endothelialization Fibrin BxVelocity D E F Strut Fibrin Neointima Source: Joner M & Finn AV. J Am Coll Cardiol. 2006 Jul 4;48(1):193-202. 36

Delayed Endothelialization Overlapping SES vs PES BMS SES BMS PES Overlap Overlap Conclusions: BMS showed far greater endothelialization than DES Lack of coverage highlighted in areas of overlap Less surface coverage by endothelial cells in PES than SES 37 Source: Finn AV. Circulation 2005

Which stent is not cobalt chromium : 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx (Tantalium) 38

Which stent is not cobalt chromium : 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx (Tantalium) 39

Which stent is not cobalt chromium : 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx (Tantalium) 40

This presentation and its content is copyright of Abbott Vascular - 2010 Abbott Vascular. All rights reserved. Any redistribution or reproduction of part or all the contents in any form is strictly prohibited. You may not, except with our express 41 written permission, distribute or commercially exploit the content. Nor may you transmit or store it in any electronic retrieval system.

Which stent is not cobalt chromium : 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx (Tantalium) 42

Which stent is not cobalt chromium : 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx (Tantalium) 43

Which stent is not cobalt chromium : 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx (Tantalium) 44

Which stent is not cobalt chromium : 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx (Tantalium) 45

Which stent is not cobalt chromium: 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx 46

Which stent is not cobalt chromium: 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx 47

DES vs BMS in STEMI : Massachusetts Registry 48

Which stent is not cobalt chromium: 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx 49

HORIZONS-AMI 3-Year Results DES vs BMS : DES BMS P-value TLR 9.4% 15.1% 0.001 TLR: No Routine Angio 8.7% 12.7% 0.01 50

SUMMARY 51

DES represent an unique step forward We did not pay sufficient attention to possible complications: only placebo has almost no complications! Efforts should concentrate to prevent: early thrombosis-technique and antiplatelets late thrombosis-innovative solutions and further understanding DES allow treatment of more complex lesions with less immediate and late complications (personal opinion!) A.Colombo: The Drug eluting stent summit, TCT 2007 52

Quick Self Assessment 53

Most important cause of stent failure is: 1. Calcified lesion 2. Under expansion 3. Tortuosity 4. Lenght 54

Most important cause of stent failure is: 1. Calcified lesion 2. Under expansion 3. Tortuosity 4. Lenght 55

In-stent postdilatation is performed with: 1. NC balloons 2. Longer balloons 3. Semi compliant balloons 4. Balloons from the stent 56

In-stent postdilatation is performed with: 1. NC balloons 2. Longer balloons 3. Semi compliant balloons 4. Balloons from the stent 57

Which are indications for DES stenting (all true EXCEPT): 1. Long lesions 2. In stent restenosis 3. Difficult anatomy (tortuosity/calcifications) 4. CTO 58

Which are indications for DES stenting (all true EXCEPT): 1. Long lesions 2. In stent restenosis 3. Difficult anatomy (tortuosity/calcifications) 4. CTO 59

Which stent doesn t belong to limus family? 1. Cypher select 2. Taxus 3. Xience V 4. Endeavor Resolute 60

Which stent doesn t belong to limus family? 1. Cypher select 2. Taxus 3. Xience V 4. Endeavor Resolute 61

BMS can be used in all situations EXCEPT : 1. Short lesions 2. Most AMI 3. Difficult anatomy 4. In stent restenosis 62

BMS can be used in all situations EXCEPT : 1. Short lesions 2. Most AMI 3. Difficult anatomy 4. In stent restenosis 63

Which stent is not stainless steel: 1. Cypher Select 2. Taxus Liberte 3. Xience V 4. Nobori 64

Which stent is not stainless steel: 1. Cypher Select 2. Taxus Liberte 3. Xience V (Cobalt chromium) 4. Nobori 65

Which stent is not cobalt chromium: 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx 66

Which stent is not cobalt chromium : 1. NEVO 2. Promus 3. Endeavor Resolute 4. Zomaxx (Tantalium) 67

Cases Review 68

Case 1 P. S. Age : 58 years Gender : female Risk factors : - hypertension - HBI 69

Location, approach, type of stent p RCA p LAD Approach Guidewire 0.014 Balloon catheter Stent to LAD intermediate 100%, thrombus trans radial BMW 2.0/20mmx10atm BMS 2.75/20mmx15atm 70

RCA 71

Prox LAD occlusion (STEMI) 72

Prox LAD occlusion (STEMI) 73

Balloon catheter 2.0/20mm/10atm pre dilatation 74

Result 75

BMS 2.75/20mm x 20atm 76

Final result 77

P. S. Two months later (p LAD : stent occlusion) 78

Location, approach, type of stent p RCA p LAD Approach Guidewire 0.014 Guidewire 0.014 Guidewire 0.014 Balloon pre dilatation Balloon pre dilatation Balloon pre dilatation Stent to LAD intermediate 100% in stent trans radial Pilot 50, 150 Hydrophilic BMW 1.5/20mmx15atm 2.0/20mmx13atm 3.0/30mmx6atm DES 3.0/28mmx15atm 79

Prox LAD : in stent occlusion 80

Balloon catheter 1.5/20mm/15atm pre dilatation 81

Result 82

Balloon catheter 2.0/20mm/13atm pre dilatation 83

Balloon catheter 2.0/20mm/13atm pre dilatation 84

Result 85

DES 3.0/28mm - positioning 86

DES 3,0/28mm x 15atm - deployment 87

Cx control 88

Final result 89

Final result 90

CASE 2 I. F. Age : 57 years Gender : male Risk factors : - hypertension - prior IM - prior PCI/stenting to p LAD 91

Location, approach, type of stent p LAD m LCx 1 st OM Approach Balloon pre dilatation Stent to p RCA Balloon post dilatation 100%+instent+thrombus 90%+TIMI flow=3 80%+TIMI flow=3 trans radial 3.5/20x10atm DES 4.0/18x16atm NC balloon 4.0/9x18atm 92

Left coronary artery 93

p LAD 100% + thrombus 94

BMW 0.014 guidewire in LAD 95

DES 4.0/18mm - positioning 96

DES 4.0/18mm x 16atm - deployment 97

Result 98

NC Balloon catheter post dilatation 4.0/9mmx18atm 99

Final result 100

Case 3 R. G. Age : 60 years Gender : female Risk factors : - hypertension - hiperlipidemia - smoker 101

Location, approach, type of stent m LAD p LCx m LCx Approach Guidewire 0.014 Guidewire 0.014 Balloon pre dilatation Balloon pre dilatation Stent to LAD 99%+TIMI flow=3 80%+TIMI flow=3 100%+CTO+collateral trans radial BMW Floppy Extra Support 2.0/20 x 15atm 2.5/15 x 15atm BMS 2.75/17x15atm 102

RCA 103

Left coronary artery 104

Balloon catheter 2.0/20mm x 15 atm 105

Balloon catheter 2.5/15mm x 15 atm 106

Result after balloon dilatation 107

BMS 2.75/17mm x 15atm 108

Final result 109